_edited.png)
RISK CONCERN
Investment Strategy, Risk Analysis, and Insights by Chartered Professionals
BAX
Primary Facts
Medical Instruments & Supplies
Name:
-
Sector:
68.00M
Industry:
56.21
CEO:
Mr. Jose Almeida
Total Employees:
Large Cap
Our Technological Advancement Rating
Our Rating:
4.141702955
-54.48206803
Baxter International Inc. (XNYS:BAX) In-Depth Stock/Fundamental/Options Analysis Today
Primary Targets/Price Insights
Previous Close ($) :
BAXTER INTERNATIONAL INC. (XNYS:BAX)
One Month Price Target:
Six Month Price Target :
$56.4
Likely Price in One Year's Time:
Ticker:
$57.35
Likely Trading Range Today Under (Normal Volatility)
$56.36
Price Upper limit ($) :
$58.49
Price Lower limit ($) :
Crash Risk Prep/Key Price Levels (High Volatility/Risk)
Price, as per data analysis, isn't likely to fall below:
Today:
P153
This week:
$54.1
This month :
$51.48
Other Primary facts
Market Cap:
503.61M
Market Cap Classification:
27.53B
Number of Shares
IPO Date:
A+
Best/Worst Daily Performance (Last 3+ Years)
Highest Daily Appreciation:
-11.63%
$46.76
Worst Daily Decline:
Our Options Trading Entry Points
Iron Condor entry points for options expiring in 1 week's time
Low risk (<2%) entry points
Buy Call:
Sell Call:
Buy Put:
Sell Put:
$61.62
12.49%
$50.80
$66.03
Medium risk (<10%) entry points
Buy Call
Sell Call
$59.24
Buy Put:
Sell Put:
$46.39
$53.18
$60.18
These entry points can be used for other strategies, such as butterflies, straddles, etc.
Risk-Adjusted returns (Sharpe Ratio) of
Medical Instruments & Supplies
Sharpe Ratio:
BAX, is amongst the top 40% lowest yielding stocks in terms of daily returns
Comparison:
1.60%
-2.691858444
Sharpe ratio is -269.19% lower than the industry
Average Returns/Yield of
Medical Instruments & Supplies
Daily returns:
1
Weekly returns:
-0.04%
Monthly returns:
-0.20%
Yearly returns:
-9.66%
Comparison of returns:
-1.657626435
Classification:
Average annual returns/yield (last 3 years) is -165.76% below industry average
Results of T-Test of Returns:
BAX is a riskier investment compared to Nasdaq (IXIC)
Statistical test of Returns:
0.05
Volatility (measured by Standard Deviation)
Daily Volatility:
& is -218.85% lower than the market/S&P 500 average
Weekly Volatility:
1.81%
Monthly Volatility:
4.05%
Yearly Volatility:
8.10%
Volitlilty of last five days (Measured by Standard Deviation)
Average Volatility of this Week:
35.32%
-23.38%
Value at Risk Analysis (VaR)
Daily VaR:
Volatility in last five trading days has been -23.38% below long-term volatility
Weekly VaR:
-3.76%
Monthly VaR:
-8.41%
How Much Can the price of
Medical Instruments & Supplies
Decline in a Recession?
Likely price decline in a recession:
Base case (decline):
Risk of crash in next 6/12 months: Low (<25%)
Worst case (decline):
$47.59
This translates to price declining to:
-15%
This translates to price declining to:
-58.27%
Severe Crash Probability
-16.82%
What is Value at Risk (VaR)?
Risk Fundamentals
1.70%
BAX is a 18.72% riskier investment compared to the market/S&P 500 & is 1.70% riskier than Nasdaq (IXIC)
BAX is a 18.72% riskier investment compared to the market/S&P 500
Beta Examination of
Medical Instruments & Supplies
0.603
Expected beta in 1 year's time:
0.598
Expected beta in 3 year's time:
0.6
Unlevered (debt free) Beta:
Beta in relation to market/S&P 500--0.60
Beta in relation to Nasdaq (XNAS):
Returns are, approximately, symmetrical
Beta in relation to all global stocks::
Beta is -39.03% below industry average
Beta Comparison & Analysis
Beta of competitors/peers::
0.226
-0.280
Average Industry Beta:
Beta is -28.03% lower than peers
-0.390283992
Sustainable Growth Rate Analysis
Sustainable growth rate for this stock/firm:
WACC is -54.52% below industry mean WACC
-46.88%
Alpha provided | Alpha Analysis
Alpha provided:
0.849
-4.561
-10.782
Analysis of Cost of Capital of
Medical Instruments & Supplies
Equity cost of capital:
Alpha is -1078% below the market average
-0.266
Unlevered (without debt) cost of capital:
Equity cost of capital is -26.64% below industry mean WACC
Before-tax cost of debt:
2.73%
After-tax cost of debt:
1.45%
Overall debt rating:
1.15%
Weighted average cost of capital (WACC):
1.45%
-54.52%
Key Per-Share Metrics & Analysis
Revenue per share:
Present value of the expected future dividends only: $26.66
Revenue growth rate per share of (3Y):
Price to sales ratio is -71.82% below the industry mean
-59.74%
EPS:
One Billion Fifty-Two Million Three Hundred Seventy-Five Thousand Six Hundred Ten Dollars
Expected Annual growth rate of EPS (3Y):
-
-24.79%
Free cash flow (FCF) per share:
Price to book ratio is -56.99% below the industry mean
Growth rate in R&D investment/expenditure is 863.68% higher than the industry
183.9222327
Debt per share
Debt repayment rate in last quarter: 2.53%
EBITDA per share
Each employee generates -62% less EBITDA than industry average revenue per employee
Valuation Analysis Today of
Medical Instruments & Supplies
P/E Ratio:
Sustainable growth rate is -46.88% below industry average
P/E Ratio of Competitors/Peers:
28.16
-0.435577145
104.2695215
-0.460916294
$2.63
Share value as per dividend discount (DDM) model: $57.00
P/S (Price to Sales ratio):
$26.90
-0.718185257
P/B (Price to book value ratio):
Price to sales ratio is -71.82% below the industry mean
-
-
Net income growth rate (3Y):
Annual revenue growth rate is -59.74% below industry average
-83.86%
Dividend Analysis
Net income growth rate is -83.86% lower than the industry average net income growth rate
Dividend payout rate: 13.25%
$0.29
Previous Dividend: $0.29
Previous adjusted dividend: $0.29
Previous Dividend: $1.13
Expected next dividend best case: $0.31
Expected next dividend worst case: $0.27
Average dividend payment (long-term): $0.26
Average dividend increase/decrease (growth rate) % per period: 2.92%
Expected next dividend payment date: 29/09/2022
Expected next dividend record date: 09/01/2022
-
Previous dividend payment date: 07/01/2022
Previous dividend record date: 06/03/2022
Dividend History:
-
2022-02-24--$0.28
2021-09-02--$0.28
2022-06-02--$0.29
2021-12-02--$0.28
2021-06-03--$0.28
-2.478240755
In-depth Debt & Leverage Analysis
Debt to equity ratio:
169.56%
Net debt to equity ratio:
The remaining useful life of property plant & equipment is: 12.9 years
Debt to assets ratio:
47.04%
Net debt to assets ratio:
190.34%
47.09%
Ability to repay debt:
Interest coverage ratio:
Debt-to-asset ratio is 47.09% above industry average
-0.86
Looking forward:
Debt growth rate:
2.1x
53.77%
2.53%
Analysis of Key Statistics
Correlation of price movement with the market:
17.09427669
Statistical significance of correlation:
-0.35%
Average Correlation of the industry with the market:
0.547
8.29%
R Squared (percentage of price movement explained by movement of the market):
0.547
Correlation of price movement with Nasdaq (^IXIC):
0.299
Covariance of price movement with the market:
0.011
Kurtosis
0.012
9.747
Skewness of returns:
Returns have a significant fat-tails (leptokurtic), i.e., returns considerably higher or lower than the mean returns are more probable, compared to assets with normally distributed returns
-0.368
Fundamental Analysis & Dupont Analysis of
Medical Instruments & Supplies
Gross Profit Margin Ratio:
5.31B
Operating Profit Margin Ratio:
Net profit margin is -41.70% lower than the industry
-18.21%
Net Profit Margin Ratio:
5.31B
Effective Tax Rate:
3.03%
-0.620899127
Dupont Method
Net Profit Margin
Return on Equity Ratio (ROE):
×
ROA
=
×
Return on assets (ROA) is -54.89% lower than the industry
-125.54%
Financial Leverage
Asset Turnover Ratio (ROA):
Operating profit margin is -18.21% lower than the industry
-54.89%
Financial Leverage:
Interest coverage ratio is -86.18% less than industry average
Current Ratio:
Return on equity (ROE) is -125.54% lower than the industry
-0.424603218
Cash Conversion Cycle (days):
$34.30
-0.154336646
Current ratio is -42.46% below industry average
Stock based compensation to net income ratio:
Equity growth rate per share is 18392.22% higher than the industry
In-depth Efficiency Analysis
Revenue generated per employee:
Cash conversion cycle is -15.43% below industry average
-0.361597603
EBITDA generated per employee:
Each employee generates -36% less revenue than industry average revenue per employee
-0.622943316
Profit generated per employee:
$5.00
-77%
Free cash flow (FCF) generated per employee:
Each employee generates -77% less net income/profit than industry average revenue per employee
-1.196931324
Assets/Capital per employee
Each employee generates -120% less free cash flow than industry average revenue per employee
-1.196931324
Research & Development (R&D) Analysis
2.50%
8.636831403
Competitors/Peer firms of
Medical Instruments & Supplies
$89.38
AGILENT TECHNOLOGIES, INC. (XNYS:A)
Takeda Pharmaceutical Company Limited (XNYS:TAK)
CENTENE CORPORATION (XNYS:CNC)
Alcon Inc. (XNYS:ALC)
IQVIA HOLDINGS INC (XNYS:IQV)
MCKESSON CORPORATION (XNYS:MCK)
VEEVA SYSTEMS INC. (XNYS:VEEV)
METTLER-TOLEDO INTERNATIONAL INC. (XNYS:MTD)
Current Analyst Ratings
$2.09
Strong buy�8%
Buy�17%
Hold�38%
Sell�4%
Strong sell�0%
Income Statement
Period:
3/31/2022
Date:
Value
Revenue:
TTM
Cost of Revenue:
Gross Profit:
R&D Expense
General & Admin Expenses:
Selling, General & Admin Expenses
Sales and Marketing Expenses
Other Expenses :
Operating Expenses :
Cost & Expenses :
Interest Income:
Interest Expenses:
Depreciation & Amortization:
EBITDA:
Operating Income:
Other Income Expenses:
Income Before Tax:
Income Tax Expense:
Net Income:
Balance Sheet
Date:
Calendar Year:
Period:
Cash & Cash Equivalents:
Short Term Investments:
Cash & Short Term Investments:
Net Receivables:
Inventory:
Other Current Assets:
Total Current Assets:
PP&E:
Goodwill:
Intangible Assets:
Long Term Investments:
Tax Assets:
Other Non-Current Assets:
Total Non-Current Assets:
Other Assets:
Total Assets:
Accounts Payable:
Short Term Debt:
Tax Payables:
Deferred Revenue:
Other Current Liabilities:
Total Current Liabilities:
Long Term Debt:
Other Non-Current Liabilities:
Total Non Current Liabilities:
Other Liabilities:
Total Liabilities:
Common Stock:
Retained Earnings:
Accumulated Other Comprehensive Loss:
Other Total Stockholders' Equity:
Total Stockholders' Equity:
Total Liabilities and Stockholders' Equity:
Total Investments:
Total Debt:
Net Debt:
13.55B
8.24B
157%
556.00M
678.00M
3.31B
-
-
12.10B
14.00M
257.00M
1.05B
75%
152.00M
- 263000.00K
37%
152.00M
Statement of Cash Flow
Date:
Period:
73.00M
Differed Income Tax :
380.00M
Stock Based Compensation :
- 55000.00K
Change in Working Capital :
32.00M
Accounts Receivables:
- 224000.00K
Other Working Capital:
5.00M
Other Non-Cash Items:
- 43000.00K
Net Cash Provided by Operating Activities:
2.00M
Investments in PP&E:
208.00M
Net Acquisitions:
-
Purchases of Investments:
- 174000.00K
Sales/Maturities of Investments:
Other Investing Activities:
Net Cash Used for Investing Activities:
Debt Repayment:
Common Stock Issued:
Common Stock Repurchased:
Dividend Paid:
Other Financing Activities:
Net Cash Used Provided by Financing Activities:
Effect of FOREX on Changes in Cash:
Net Changes in Cash:
Cash at End of Period:
Cash at Beginning of Period:
Operating Cash Flow:
Capital Expenditure:
Free Cash Flow (FCF):
Value
3/31/2022
2022
Q1
2.29B
-
2.29B
2.47B
2.55B
860.00M
8.17B
5.72B
9.82B
7.69B
-
-
1.31B
24.54B
-
32.72B
1.22B
409.00M
-
-
2.26B
3.89B
17.27B
2.43B
19.71B
-
23.60B
683.00M
16.99B
- 3387000.0K
Value
3.86B
-
9.08B
32.67B
-
17.68B
-
-
- 130000.00K
- 304000.00K
- 449000.00K
-
-
- 140000.00K
41.00M
- 548000.00K
- 13000.00K
- 657000.00K
2.30B
2.96B
208.00M
- 140000.00K
Our Proprietary Portfolio Rating
Our Rating:
1386.378853
Price Forecast/Expected Price in Next 5 Years of
Medical Instruments & Supplies
2023
2024
2025
2026
2027
76.24141605
$58.78
$79.33
$82.55
$85.89